| Literature DB >> 30023526 |
Mona A Mohamed1, Shimaa A Atty1, Ali M Yehia2, Christopher W Foster3, Craig E Banks3, Nageh K Allam4.
Abstract
Cesium-gold (Cs-Au) nanoparticles are shown to be analytically advantageous for the electroanalytical sensing of dapoxetine (DPX), a serotonin reuptake inhibitor used for the treatment of premature ejaculation. The Cs-Au nanoparticles are electrically wired and supported upon mass producible, economical screen-printed electrochemical sensing platforms and are characterized electrochemically (cyclic voltammetry and electrochemical impedance spectroscopy) and physiochemically (field emission scanning electron microscopy and energy dispersive X-ray analysis). The face-centered design was applied to optimize the significant experimental factors by using square wave voltammetry. The Cs-Au-based sensor is found to exhibit a large linear range (10-7 to 10-4 M) with a good analytical linearity with the limits of detection and quantification corresponding to 2.50 × 10-10 and 8.33 × 10-8 M, respectively. The developed sensor was successfully applied in the quantification of DPX in the presence of sildenafil, both of which are commonly found within combined dose tablet pharmaceutical formulations. The proposed DPX electrochemical Cs-Au-based sensor has the advantages of being single-shot and disposable and is shown to be successful in determining DPX in pharmaceutical formulations, human urine, and serum samples with acceptable recoveries.Entities:
Year: 2017 PMID: 30023526 PMCID: PMC6044806 DOI: 10.1021/acsomega.7b01193
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Cyclic voltammograms of 1.0 mM DPX in the B–R buffer (pH 2.0) at a scan rate of 0.10 V s–1 recorded using SPE, Cs/SPE, Au/SPE, and Cs–Au/SPE.
Levels of Studied Factors for Sixteen Experiments in the RSM Design with the Obtained Response
| factors’
level | response | ||||
|---|---|---|---|---|---|
| experiment number | pattern | scan rate (mV/s) | deposition time (s) | pH | current (μA) |
| 1 | +–+ | 50 | 30 | 4 | 42 |
| 2 | –+– | 10 | 90 | 2 | 49 |
| 3 | 0 | 30 | 60 | 3 | 41 |
| 4 | 0a0 | 30 | 30 | 3 | 33 |
| 5 | +–– | 50 | 30 | 2 | 46 |
| 6 | ++– | 50 | 90 | 2 | 58 |
| 7 | a00 | 10 | 60 | 3 | 31 |
| 8 | ––– | 10 | 30 | 2 | 29 |
| 9 | –++ | 10 | 90 | 4 | 36 |
| 10 | A00 | 50 | 60 | 3 | 59 |
| 11 | +++ | 50 | 90 | 4 | 57 |
| 12 | 00A | 30 | 60 | 4 | 47 |
| 13 | 0A0 | 30 | 90 | 3 | 42 |
| 14 | 0 | 30 | 60 | 3 | 40 |
| 15 | ––+ | 10 | 30 | 4 | 22 |
| 16 | 00a | 30 | 60 | 2 | 42 |
Figure 2Surface plots summarizing the effects of different experimental parameters: (A) scan rate/deposition time, (B) pH/scan rate, and (C) deposition time/pH upon the voltammetric current/analytical signal.
Figure 3Square wave voltammograms using the Cs–Au/SPE sensors recorded in pH 2.0 B–R buffer corresponding to (A) 1.0 × 10–7 to 1.1 × 10–3 M DPX and (B) 5.0 × 10–8 to 1.1 × 10–3 SIL. (C) Square wave voltammograms of 6.6 × 10–7 to 1.0 × 10–4 M DPX in the presence of 5.0 × 10–8 to 6.0 × 10–5 M SIL at a scan rate of 0.05 V s–1 and their corresponding calibration curves.
Determination of DPX in a Pharmaceutical Formulation and Human Plasma Sample Using the New Proposed Sensing Protocola
| sample | amount added (μM) | amount found (μM) | apparent recovery % |
|---|---|---|---|
| human blood plasma | 8.00 | 8.01 | 100.13% |
| DPX | 20.00 | 19.89 | 99.45% |
| 70.00 | 69.97 | 99.96% | |
| recovery % ± RSD | 99.85% ± 0.354 | ||
| SIL | 0.40 | 0.399 | 99.75% |
| 1.00 | 1.001 | 100.10% | |
| 40.00 | 39.95 | 99.88% | |
| recovery % ± RSD | 99.91% ± 0.177 | ||
| human urine | 6.00 | 5.96 | 99.33% |
| DPX | 30.00 | 30.12 | 100.40% |
| 80.00 | 80.09 | 100.11% | |
| recovery % ± RSD | 99.95% ± 0.553 | ||
| SIL | 0.60 | 0.597 | 99.50% |
| 1.50 | 1.509 | 100.60% | |
| 30.00 | 30.25 | 100.83% | |
| recovery % ± RSD | 100.31% ± 0.711 | ||
| Joypox (60 mg/tablet) | 4.00 | 3.97 | 99.25% |
| 15.00 | 14.91 | 99.00% | |
| DPX | 90.00 | 89.95 | 99.94% |
| recovery % ± RSD | 99.39% ± 0.487 |
Average of three determinations. RSD, relative standard deviation.